Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Vaccines caused blood clots !!!!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(100)
•••
Comment by GajjarDron Mar 12, 2021 11:07am
158 Views
Post# 32785149

RE:Vaccines caused blood clots !!!!!

RE:Vaccines caused blood clots !!!!!What is more concerning is how the mutated versions may effect people vaccinated morose with immune system being compromised of their own vital abilities to ward off viruses. People should rewind tape back to SWINE FLU (a.k.a ~ Sars1). Now here we are Sars Two .... why not masks then ? Where did it go? Masks stop people from breathing benefits of musocal factors, and not going outside is like suicide so much beneficial bacteria.
loserme wrote: Vaccines for COVID are causing blood clots and that will lead to strokes and heart attacks.  I just canceled my appointment after I heard the news today. I am more than willingly to take the r107, NO has been approved by FDA. Great news for KLY


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities